CD1a-restricted T-cell receptor
A CD1a-restricted T-cell receptor discovery enabling novel immunotherapies, diagnostics, and immune monitoring approaches for cancer and inflammatory diseases.
Identification of CD1a-reactive T cell receptors, including a shared alpha chain sequence found across multiple donors. This discovery enables new approaches to detect, study, and therapeutically target CD1a-expressing cells in cancer and inflammatory diseases.
Applications: TCR-based immunotherapy, bispecific TCR therapeutics, cancer diagnostics, inflammation biomarkers, immune monitoring, CD1a-targeted drug development
| Features | Benefits |
|---|---|
| Function confirmed by TCR transfer via CRISPR HDR into cells with CD1a-specific activation | Broad applicability across inflammatory skin and mucosal conditions and CD1a-expressing malignancies |
| Invariant CD1a-reactive TCR alpha chain across donors | Therapeutic potential: Enables TCR-T and bispecific therapies targeting CD1a, with a particular relevance to skin inflammation, as well as subsets of lymphoma and other CD1a-expressing cancers |
| Conserved core motif with defined CDR1/2 patterns useful for engineering | Diagnostic utility: Shared TCRs serve as biomarkers for CD1a-reactive T cells |
| Extensive functional validation of TCRs, including via transfer into recipient T cells | Research advancement: Faster lead discovery and optimisation using the shared motif and defined sequence templates |
| Novel robust isolation and expansion workflow using CD1a multimers, cytokine capture, single-cell cloning | High functional avidity and mechanism validated in transfer assays, de-risking translation |
| Sequence-resolved panel of alpha/beta TCRs with specified CDRs and V/J usage |